Robert Davis - Intra Cellular Insider

ITCI -- USA Stock  

USD 20.28  0.52  2.50%

  President
Mr. Robert E. Davis is Ph.D., is Senior Vice President and Chief Scientific Officer of the Company. He previously served as President and CEO of 3D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at ParkeDavis Pharmaceutical Research, WarnerLambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimers disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease
Age: 65  President Since 2015  Ph.D    
646-440-9333  http://www.intracellulartherapies.com
Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.

Robert Davis Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (17.14) % which means that it has lost $17.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.39) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.

Intra Cellular Thera Leadership Team

Lawrence Wennogle, Vice President of Drug Discovery
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Independent Director
Richard Lerner, Director
Robert Davis, Senior Vice President and Chief Scientific Officer
Allen Fienberg, Co-Founder and VP of Bus. Devel.
Michael Halstead, Sr. VP, General Counsel and Secretary
Sharon Mates, Co-Founder, Chairman, CEO and Pres
Andrew Satlin, Executive Vice President and Chief Medical Officer
Juan Sanchez, Vice President - Corporate Communications and Investor Relations
Rory Riggs, Independent Director
Joel Marcus, Director
Kimberly Vanover, VP of Clinical Devel.
Lawrence Hineline, Vice President and CFO

Stock Performance Indicators

Current Sentiment - ITCI

Intra Cellular Thera Investor Sentiment
Most of Macroaxis users are currently bullish on Intra Cellular Therapies. What is your judgment towards investing in Intra Cellular Therapies? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">